Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. The index has shown a price loss of -57.30% this year. Over the last six months, there has been a stronger performance of -35.96%. The price of CYCC fallen by 11.76% during the last 30 days period. For the last 5-days stocks have improved 42.50%.
In terms of market performance, Cyclacel Pharmaceuticals Inc had a somewhat inconsistent run in. The highest value for the stock in the past year was $11.34 on 10/19/23, while the lowest value was $0.75 on 10/10/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of CYCC Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Cyclacel Pharmaceuticals Inc’s current trading price is -89.95% away from its 52-week high, while its distance from the 52-week low is 52.00%. The stock’s price range for this period has been between $0.75 and $11.34. The Healthcare sector company’s shares saw a trading volume of about 14.31 million for the day, which was higher than the average daily volume of 68460.0 over the last three months.
The Connection Between Financial Performance and Market Capitalization
Cyclacel Pharmaceuticals Inc (CYCC) has experienced a quarterly decline of -30.91% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.45M.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.3957, with a change in price of -0.8700. Similarly, Cyclacel Pharmaceuticals Inc recorded 251,226 in trading volume during the last 100 days, posting a change of -43.28%.
CYCC’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for CYCC stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.
CYCC Stock Stochastic Average
As of today, the raw stochastic average of Cyclacel Pharmaceuticals Inc over the last 50 days is at 31.45%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 31.45%. Further, the company’s Stochastic %K and %D values for the last 20 days were 51.23% and 42.85%, respectively.
